TSRF 786C
Alternative Names: TSRF-786-CLatest Information Update: 03 Sep 2021
At a glance
- Originator Tasrif Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Brain cancer; Cancer
Most Recent Events
- 25 Aug 2021 TSRF 786C is available for licensing as of 25 Aug 2021. https://tasrifpharmaceutical.org/contact-2/
- 25 Aug 2021 Tasrif Pharmaceutical has a pending CIP in the US
- 25 Aug 2021 Tasrif Pharmaceutical has patent protection for poliovirus receptor specific humanized monoclonal antibodies in the US